Bahl & Gaynor Inc. Buys 40 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bahl & Gaynor Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,331 shares of the medical research company’s stock after purchasing an additional 40 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Thermo Fisher Scientific were worth $1,936,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 33,095,791 shares of the medical research company’s stock worth $19,235,605,000 after buying an additional 117,353 shares in the last quarter. Capital Research Global Investors boosted its position in Thermo Fisher Scientific by 6.9% during the fourth quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock valued at $4,240,824,000 after purchasing an additional 517,137 shares in the last quarter. Norges Bank purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $2,909,524,000. Franklin Resources Inc. raised its stake in shares of Thermo Fisher Scientific by 16.0% in the fourth quarter. Franklin Resources Inc. now owns 2,518,760 shares of the medical research company’s stock worth $1,336,933,000 after purchasing an additional 347,560 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Thermo Fisher Scientific by 3.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,349,580 shares of the medical research company’s stock worth $1,247,134,000 after purchasing an additional 69,132 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft raised their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Jefferies Financial Group reissued a “buy” rating and issued a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. HSBC raised their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $605.63.

Thermo Fisher Scientific Stock Up 1.0 %

TMO traded up $5.48 on Tuesday, hitting $551.90. 1,360,089 shares of the company were exchanged, compared to its average volume of 1,527,768. The firm has a 50-day moving average price of $564.16 and a two-hundred day moving average price of $564.77. The company has a market cap of $210.67 billion, a price-to-earnings ratio of 35.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last three months, insiders sold 22,000 shares of company stock valued at $12,532,780. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.